|
US4401756A
(en)
|
1981-04-14 |
1983-08-30 |
Immunex Corporation |
Process for preparing human interleukin 2
|
|
DE3377363D1
(en)
|
1982-03-31 |
1988-08-18 |
Ajinomoto Kk |
Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4992271A
(en)
|
1982-09-23 |
1991-02-12 |
Cetus Corporation |
Formulation for lipophilic IL-2 proteins
|
|
US4470461A
(en)
|
1982-09-30 |
1984-09-11 |
Phillips Petroleum Company |
Organic nitro compounds as cosurfactants in enhanced oil recovery processes
|
|
US4588585A
(en)
|
1982-10-19 |
1986-05-13 |
Cetus Corporation |
Human recombinant cysteine depleted interferon-β muteins
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US7198919B1
(en)
|
1983-04-25 |
2007-04-03 |
Genentech, Inc. |
Use of alpha factor sequences in yeast expression systems
|
|
US4512584A
(en)
|
1983-06-24 |
1985-04-23 |
Western Publishing Company, Inc. |
Improved game board with pieces cooperating for rotation
|
|
US4656132A
(en)
|
1984-03-28 |
1987-04-07 |
Cetus Corporation |
Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
|
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
|
US4569790A
(en)
|
1984-03-28 |
1986-02-11 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
|
|
US4604377A
(en)
|
1984-03-28 |
1986-08-05 |
Cetus Corporation |
Pharmaceutical compositions of microbially produced interleukin-2
|
|
DE3583880D1
(de)
|
1984-04-09 |
1991-10-02 |
Takeda Chemical Industries Ltd |
Stabile interleukin-2-zusammensetzung.
|
|
US4569794A
(en)
|
1984-12-05 |
1986-02-11 |
Eli Lilly And Company |
Process for purifying proteins and compounds useful in such process
|
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
US4752585A
(en)
|
1985-12-17 |
1988-06-21 |
Cetus Corporation |
Oxidation-resistant muteins
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4748234A
(en)
|
1985-06-26 |
1988-05-31 |
Cetus Corporation |
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
|
|
US4766106A
(en)
*
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5102872A
(en)
|
1985-09-20 |
1992-04-07 |
Cetus Corporation |
Controlled-release formulations of interleukin-2
|
|
US5643565A
(en)
|
1985-09-20 |
1997-07-01 |
Chiron Corporation |
Human IL-2 as a vaccine adjuvant
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US4879111A
(en)
|
1986-04-17 |
1989-11-07 |
Cetus Corporation |
Treatment of infections with lymphokines
|
|
US4849329A
(en)
|
1986-05-30 |
1989-07-18 |
E. I. Du Pont De Nemours And Company |
Process for preparing lymphokine activated killer cells
|
|
US4931544A
(en)
|
1986-09-04 |
1990-06-05 |
Cetus Corporation |
Succinylated interleukin-2 for pharmaceutical compositions
|
|
US5037644A
(en)
|
1986-10-27 |
1991-08-06 |
Cetus Corporation |
Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
|
|
US4938956A
(en)
|
1987-04-01 |
1990-07-03 |
International Minerals & Chemical Corp. |
Synergistic immunostimulating composition and method
|
|
US4931543A
(en)
|
1987-05-11 |
1990-06-05 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
US5078997A
(en)
|
1988-07-13 |
1992-01-07 |
Cetus Corporation |
Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
|
|
FR2635527B1
(fr)
|
1988-07-28 |
1992-06-12 |
Roussel Uclaf |
Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
US5830452A
(en)
|
1990-11-20 |
1998-11-03 |
Chiron Corporation |
Method for enhancing the anti-tumor therapeutic index of interleukin-2
|
|
DE69123241T2
(de)
|
1990-12-14 |
1997-04-17 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
US5445090A
(en)
|
1991-07-25 |
1995-08-29 |
Mim Industries, Inc. |
Interchangeable clamp for use in a sewing machine
|
|
US5858784A
(en)
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5320663A
(en)
|
1992-07-02 |
1994-06-14 |
E. I. Du Pont De Nemours And Company |
Method of obtaining lead and organolead from contaminated media using metal accumulating plants
|
|
EP0599303A3
(en)
|
1992-11-27 |
1998-07-29 |
Takeda Chemical Industries, Ltd. |
Peptide conjugate
|
|
US5419900A
(en)
|
1993-05-19 |
1995-05-30 |
The United States Of America As Represented By The Department Of Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
US5696079A
(en)
|
1993-05-19 |
1997-12-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunologic enhancement with intermittent interleukin-2 therapy
|
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
US5696234A
(en)
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
|
US5650234A
(en)
|
1994-09-09 |
1997-07-22 |
Surface Engineering Technologies, Division Of Innerdyne, Inc. |
Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
|
|
US6410008B1
(en)
|
1994-12-12 |
2002-06-25 |
Beth Israel Hospital Association |
Chimeric IL-10 proteins and uses thereof
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6451308B1
(en)
|
1996-04-26 |
2002-09-17 |
Beth Israel Deaconess Medical Center |
Antagonists of interleukin-15
|
|
EP0814041B1
(en)
|
1996-06-17 |
2001-11-14 |
C.P. Bourg S.A. |
A method of sheet rotation and a sheet stacker with a sheet rotator
|
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
|
US6448369B1
(en)
|
1997-11-06 |
2002-09-10 |
Shearwater Corporation |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
|
DK1411075T3
(da)
|
1998-03-12 |
2008-10-27 |
Nektar Therapeutics Al Corp |
Fremgangsmåde til fremstilling af polymerkonjugater
|
|
JP2002506980A
(ja)
|
1998-03-20 |
2002-03-05 |
ジェンザイム・コーポレーション |
新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6929791B2
(en)
|
1998-07-16 |
2005-08-16 |
Institut Pasteur |
Peptides of IL-2 and derivatives thereof
|
|
US6168785B1
(en)
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
|
ATE407697T1
(de)
|
1999-07-13 |
2008-09-15 |
Bolder Biotechnology Inc |
Erythropoietin immunglobulin fusionsproteine
|
|
US7662368B2
(en)
|
1999-07-16 |
2010-02-16 |
Institut Pasteur |
Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
|
|
JP4793971B2
(ja)
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
AU781839B2
(en)
|
1999-12-22 |
2005-06-16 |
Nektar Therapeutics |
Sterically hindered derivatives of water soluble polymers
|
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
|
AU2001227966A1
(en)
|
2000-01-20 |
2001-07-31 |
Chiron Corporation |
Methods for treating tumors
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
EP2042196B1
(en)
|
2001-10-10 |
2016-07-13 |
ratiopharm GmbH |
Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
|
WO2005016380A1
(en)
|
2003-07-30 |
2005-02-24 |
Chiron Corporation |
Methods of therapy for chronic lymphocytic leukemia
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
BRPI0508470A
(pt)
|
2004-03-05 |
2007-07-31 |
Chiron Corp |
sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
|
|
CN1930300A
(zh)
*
|
2004-03-05 |
2007-03-14 |
希龙公司 |
预测患者治疗药物耐受性的体外试验系统
|
|
US20060199250A1
(en)
|
2005-03-04 |
2006-09-07 |
Huimin Zhao |
Method for generating a mutant protein which efficiently binds a target molecule
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
CA2644513A1
(en)
|
2006-03-03 |
2007-09-07 |
London Health Sciences Centre Research Inc. |
Preventing il-2 mediated inflammation in epithelial cells
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
EP2406284B9
(en)
|
2009-03-10 |
2017-03-01 |
Biogen MA Inc. |
Anti-bcma antibodies
|
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
WO2011155607A1
(ja)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ－３抗体
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
ES2811624T3
(es)
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
KR101815323B1
(ko)
|
2011-09-08 |
2018-01-05 |
삼성전자주식회사 |
복수의 무선 전력 수신기로부터 무선 전력 공급기에 신호를 송신하는 방법 및 장치
|
|
AU2013239366A1
(en)
|
2012-03-29 |
2014-10-16 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the BC loop of human PD1
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
WO2014201378A1
(en)
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
|
JP6417419B2
(ja)
|
2013-09-04 |
2018-11-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
免疫調節剤として有用な化合物
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
MX385194B
(es)
|
2014-02-21 |
2025-03-14 |
Nektar Therapeutics India Pvt Ltd |
Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
|
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
GB2538666A
(en)
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
EP3202052B1
(en)
|
2014-09-29 |
2018-11-07 |
Telefonaktiebolaget LM Ericsson (publ) |
Interference and/or power reduction for multiple relay nodes using cooperative beamforming
|
|
EP3022589B1
(en)
|
2014-10-01 |
2024-01-03 |
Ocean Floor Geophysics Inc. |
Compensation of magnetic data for autonomous underwater vehicle mapping surveys
|
|
PT3215532T
(pt)
|
2014-11-06 |
2019-12-18 |
Hoffmann La Roche |
Anticorpos anti-tim3 e métodos de utilização
|
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
CA2978892A1
(en)
|
2015-03-06 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
NZ734650A
(en)
|
2015-03-10 |
2023-07-28 |
Aurigene Oncology Ltd |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
EP3267985A4
(en)
|
2015-03-10 |
2018-07-25 |
Aurigene Discovery Technologies Limited |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
WO2017027422A1
(en)
|
2015-08-07 |
2017-02-16 |
Alexo Therapeutics Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
US20190060407A1
(en)
|
2015-09-10 |
2019-02-28 |
Assistance Publique - Hôpitaux De Paris |
Use of interleukin 2 for treating spondyloarthritis
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
EP3364944B1
(en)
|
2015-10-22 |
2024-06-12 |
Iltoo Pharma |
Pharmaceutical compositions of il-2
|
|
KR102876923B1
(ko)
|
2015-10-23 |
2025-10-28 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
US20190022239A1
(en)
|
2016-01-19 |
2019-01-24 |
The University Of Western Australia |
Novel biomolecule conjugates and uses therefor
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
US10459951B2
(en)
|
2016-07-30 |
2019-10-29 |
Wipro Limited |
Method and system for determining automation sequences for resolution of an incident ticket
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
CN116970059A
(zh)
*
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
WO2019028419A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Ｉｌ−１５バリアントおよびその使用
|
|
CN112004829A
(zh)
*
|
2018-03-12 |
2020-11-27 |
南克维斯特公司 |
Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
JP7637415B2
(ja)
*
|
2018-06-22 |
2025-02-28 |
キュージーン インコーポレイテッド |
インターロイキン－２バリアントおよびその使用方法
|
|
CN120463822A
(zh)
|
2018-09-27 |
2025-08-12 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
CN115038453A
(zh)
|
2020-01-14 |
2022-09-09 |
辛德凯因股份有限公司 |
具有改变的icd stat信号转导的cd122
|
|
CN121319219A
(zh)
|
2020-01-14 |
2026-01-13 |
辛德凯因股份有限公司 |
Il2突变蛋白
|